We spent $4.6 trillion fighting covid-19. Meanwhile, antibiotic-resistant bacteria killed 1.27 million people in 2019 alone — more than HIV or malaria individually, and we’ve invested significantly less in stopping them.

This isn’t funding oversight. It’s a bet that the next pandemic will be viral. It won’t be.

By 2050, drug-resistant infections are projected to kill 39 million people — more than cancer. Three deaths every minute from bacteria once defeated with a pill. And, the pipeline to stop them is collapsing. Major pharmaceutical companies, including Novartis, AstraZeneca, Sanofi and Eli Lilly have abandoned antibiotic research. Not because the science is too hard but because it does not turn into a profit. Antibiotics are designed to be used sparingly, which is terrible for quarterly earnings.

The consequences are already visible. Achaogen developed a drug for multidrug-resistance infections, won FDA approval and then filed for bankruptcy less than a year later; total sales went under $1 million. Melinta Therapeutics had four antibiotics on the market and still filed for Chapter 11 bankruptcy.

Today, only 12 “innovative” antibiotics are in development globally, and only four target at least one WHO “critical” pathogen. Compare that to over 1,600 cancer drugs in trials. We’ve discovered almost no new antibiotic classes for serious Gram-negative infections in nearly 40 years.

Policy solutions like subscription-based payment models where governments pay for access rather than volume have bipartisan support but remain stalled. The UK has piloted it; the U.S. hasn’t moved.

We mobilized trillions of dollars for a virus that announced itself with a cough. The bacterial crisis announces itself with silence until antibiotics stop working. By then, the cost will not be measured in dollars. It will be measured in surgeries we can’t perform, cancers we can’t treat and infections we can’t cure.

The question isn’t whether or not this crisis is coming. It’s whether or not anyone will be ready.